Country: United States
Language: English
Source: NLM (National Library of Medicine)
PHENOXYBENZAMINE HYDROCHLORIDE (UNII: X1IEG24OHL) (PHENOXYBENZAMINE - UNII:0TTZ664R7Z)
Concordia Pharmaceuticals Inc.
PHENOXYBENZAMINE HYDROCHLORIDE
PHENOXYBENZAMINE HYDROCHLORIDE 10 mg
ORAL
PRESCRIPTION DRUG
Conditions where a fall in blood pressure may be undesirable; hypersensitivity to the drug or any of its components.
Dibenzyline (phenoxybenzamine hydrochloride) capsules, 10 mg, in bottles of 100 (NDC 59212-001-01) and (NDC 59212-001-02)
New Drug Application
DIBENZYLINE - PHENOXYBENZAMINE HYDROCHLORIDE CAPSULE CONCORDIA PHARMACEUTICALS INC. ---------- RX ONLY PRESCRIBING INFORMATION DIBENZYLINE (PHENOXYBENZAMINE HYDROCHLORIDE CAPSULES, USP) 10 MG ADRENERGIC, _ALPHA_-RECEPTOR-BLOCKING AGENT DESCRIPTION Each Dibenzyline capsule, with red cap and body, is imprinted WPC 001 and 10 mg, and contains 10 mg of Phenoxybenzamine Hydrochloride USP. Inactive ingredients consist of D&C Red No. 33, and FD&C Red No. 3, FD&C Yellow No. 6, Gelatin NF, and Lactose NF. Dibenzyline is _N_-(2-Chloroethyl)-_N_-(1-methyl-2-phenoxyethyl)benzylamine hydrochloride: Phenoxybenzamine hydrochloride is a colorless, crystalline powder with a molecular weight of 340.3, which melts between 136° and 141°C. It is soluble in water, alcohol and chloroform; insoluble in ether. CLINICAL PHARMACOLOGY Dibenzyline (phenoxybenzamine hydrochloride) is a long-acting, adrenergic, _alpha_- receptor-blocking agent, which can produce and maintain "chemical sympathectomy" by oral administration. It increases blood flow to the skin, mucosa and abdominal viscera, and lowers both supine and erect blood pressures. It has no effect on the parasympathetic system. Twenty to 30 percent of orally administered phenoxybenzamine appears to be absorbed in the active form. The half-life of orally administered phenoxybenzamine hydrochloride is not known; however, the half-life of intravenously administered drug is approximately 24 hours. Demonstrable effects with intravenous administration persist for at least 3 to 4 days, and the effects of daily administration are cumulative for nearly a week. INDICATION AND USAGE Dibenzyline is indicated in the treatment of pheochromocytoma, to control episodes of hypertension and sweating. If tachycardia is excessive, it may be necessary to use a ® 1 1 _beta_-blocking agent concomitantly. CONTRAINDICATIONS Conditions where a fall in blood pressure may be undesirable; hypersensitivity to the drug or any of its components. WARNING Dibenzyline-induced _alpha_-adrenergic blockade leaves _beta_- Read the complete document